Pharmaceutical News
-
Glenmark Launches Generic Lacosamide Injection in U.S. Market
Glenmark Pharmaceuticals Inc. has launched Lacosamide Injection USP, a generic equivalent to Vimpat® Injection, in the U.S. market. This product aims to enhance Glenmark’s U.S. portfolio and improve patient access to affordable treatments. The Vimpat market generated approximately $15.2 million in annual sales as of April 2026. Read more
-
Takeda Records JPY 402.5 Billion Legal Provision After AMITIZA Verdict
Takeda has revised its fiscal year 2025 earnings report due to the AMITIZA® antitrust litigation verdict, recording an additional legal provision of JPY 402.5 billion and related tax benefits of JPY 58.4 billion. Despite these changes, the company’s core results, FY2026 forecasts, and dividends remain unaffected, maintaining growth momentum. Read more
-
EULAR 2026 Data Highlight UCB’s CIMZIA Consistency Across RF Levels in RA
UCB presented findings at EULAR 2026 showing that CIMZIA (certolizumab pegol) maintains consistent efficacy in rheumatoid arthritis regardless of rheumatoid factor levels. The study revealed that RF antibodies bind to Fc-containing biologics but not to CIMZIA, which does not form immune complexes or induce cytokine release, supporting personalized treatment decisions. Read more
-
ASCO Data Show AstraZeneca’s EMERALD-3 Trial Marks Breakthrough in Unresectable Liver Cancer
AstraZeneca’s Phase III EMERALD-3 trial revealed that the combination of IMFINZI, IMJUDO, lenvatinib, and transarterial chemoembolization (TACE) significantly improved progression-free survival in patients with unresectable hepatocellular carcinoma (HCC). This regimen reduced disease progression risk by 30%, with median progression-free survival of 13.0 months versus 9.8 months for TACE alone. Read more
-
ASCO Data Show AstraZeneca’s Camizestrant Delayed Cancer Progression in SERENA-6
AstraZeneca’s Phase III SERENA-6 trial demonstrated that switching to camizestrant plus a CDK4/6 inhibitor significantly delays disease progression in HR-positive, HER2-negative advanced breast cancer with emerging ESR1 mutations. The trial showed a 56% reduction in progression risk, with median progression-free survival extending to 16.0 months compared to 9.2 months. Read more
-
Sanofi Launches Action 2026: Employee Share Purchase Plan
Sanofi has launched Action 2026, a global employee share purchase plan opening on June 9, 2026, for approximately 75,000 employees in 52 countries. Eligible participants can buy shares at €59.87, receiving matching shares. The initiative aims to enhance employee ownership and align interests with the company’s long-term growth strategy. Read more
-
UCB Dapirolizumab Pegol: Promising Results in Lupus Treatment at EULAR 2026
UCB presented Phase III data at EULAR 2026 demonstrating that dapirolizumab pegol (DZP) effectively reduces disease flares in systemic lupus erythematosus (SLE) while allowing for glucocorticoid tapering. Patients maintained disease control with fewer flare rates and improved immunological markers, supporting DZP’s potential in lupus treatment. Read more
-
FDA Approves NATCO and Lupin’s Eribulin Injection Targeting $43.7 Million U.S. Market
NATCO Pharma and Lupin received FDA approval for Eribulin Mesylate Injection, a generic version of Halaven®, enhancing their oncology portfolio in the U.S. This product is indicated for patients with advanced metastatic breast cancer and liposarcoma. Estimated annual sales for Halaven® are $43.7 million, supporting treatment accessibility. Read more
-
MannKind Advances Nintedanib DPI Trials for Idiopathic Pulmonary Fibrosis
MannKind has completed patient randomization in its U.S. Phase 1b INFLO-1 trial and enrolled the first patient in the global Phase 2 INFLO-2 study for nintedanib dry powder inhalation, aimed at treating idiopathic pulmonary fibrosis. Key data are expected in the third quarter of 2026, advancing this therapeutic pipeline. Read more
-
EMA and AMA Join Forces to Combat Bundibugyo Ebola Outbreak
The EMA, in collaboration with the AMA and African regulators, has initiated a coordinated response to the Ebola outbreak in the DRC and Uganda caused by the Bundibugyo virus. They aim to develop and evaluate vaccines and therapies, addressing the urgent need for effective countermeasures as there are currently no approved treatments for this strain. Read more
-
Amgen To Present New UPLIZNA and TAVNEOS Data at EULAR 2026
Amgen will showcase new clinical and real-world evidence for its drugs UPLIZNA and TAVNEOS at the EULAR 2026 conference in London. Presentations will include insights from the MITIGATE study on IgG4-related disease and real-world data on ANCA-associated vasculitis, aiming to enhance understanding of treatment outcomes and disease management. Read more
-
Sanofi Expands accelRare Platform With Biogen to Speed Rare Disease Diagnosis
Sanofi announced that Biogen joined the accelRare platform to improve the diagnosis of rare diseases in France. This initiative aims to reduce significant diagnostic delays for the nearly 3 million affected individuals. With over 310 diseases covered, accelRare has facilitated 7,000 pre-diagnoses, enhancing patient referrals and specialist care. Read more